TAPBP and prostate carcinoma: Our findings suggest that TAPBP is involved in the immune response and antigen presentation in prostate cancer, and it is negatively correlated with the occurrence of prostate cancer and adverse clinical features (such as higher PSA levels, higher malignancy, tumor metastasis, etc.).